scholarly article | Q13442814 |
P356 | DOI | 10.3109/14756366.2014.959512 |
P698 | PubMed publication ID | 25383419 |
P50 | author | Ondrej Holas | Q59661895 |
Martin Doležal | Q63663861 | ||
Pavel Ondrejček | Q85935445 | ||
P2093 | author name string | Martin Dolezal | |
Ondrej Holas | |||
Pavel Ondrejcek | |||
P2860 | cites work | Enoyl acyl carrier protein reductase inhibitors: a patent review (2006 - 2010). | Q37886187 |
Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds. | Q37979307 | ||
Metabolism of the antituberculosis drug ethionamide | Q38065214 | ||
Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 4'-substituted triclosan derivatives. | Q40384446 | ||
Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis | Q42708829 | ||
Chemical synthesis and biological evaluation of triazole derivatives as inhibitors of InhA and antituberculosis agents. | Q42719254 | ||
Dithiocarbamates strongly inhibit the β-class carbonic anhydrases from Mycobacterium tuberculosis | Q44803551 | ||
Inhibition of the β-class carbonic anhydrases from Mycobacterium tuberculosis with carboxylic acids | Q44841721 | ||
Structural basis for the variation in triclosan affinity to enoyl reductases | Q45069470 | ||
The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action | Q47215316 | ||
Dihalogenated sulfanilamides and benzolamides are effective inhibitors of the three β-class carbonic anhydrases fromMycobacterium tuberculosis | Q58863161 | ||
The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance | Q24631332 | ||
Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate | Q27618301 | ||
Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan | Q27619680 | ||
Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data | Q27640586 | ||
Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides | Q27647576 | ||
Triclosan Derivatives: Towards Potent Inhibitors of Drug-Sensitive and Drug-ResistantMycobacterium tuberculosis | Q27653366 | ||
Slow-Onset Inhibition of the FabI Enoyl Reductase from Francisella tularensis : Residence Time and in Vivo Activity | Q27653711 | ||
A Slow, Tight Binding Inhibitor of InhA, the Enoyl-Acyl Carrier Protein Reductase from Mycobacterium tuberculosis | Q27660104 | ||
Time-Dependent Diaryl Ether Inhibitors of InhA: Structure-Activity Relationship Studies of Enzyme Inhibition, Antibacterial Activity, and in vivo Efficacy | Q27682088 | ||
Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis | Q27687048 | ||
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings | Q27861111 | ||
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa | Q28272340 | ||
Triclosan targets lipid synthesis | Q28279853 | ||
Mycolic acids: structure, biosynthesis and physiological functions | Q28289888 | ||
Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated Mycobacterium tuberculosis | Q28487562 | ||
Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis | Q33260049 | ||
Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors | Q33292548 | ||
Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions. | Q33917913 | ||
Drug-target residence time: critical information for lead optimization. | Q34054343 | ||
Discovery of new inhibitors of Mycobacterium tuberculosis InhA enzyme using virtual screening and a 3D-pharmacophore-based approach. | Q34867906 | ||
Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death | Q35008349 | ||
Drug-target residence time and its implications for lead optimization | Q36556505 | ||
Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis | Q36754701 | ||
Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors | Q36800124 | ||
Diversity in enoyl-acyl carrier protein reductases | Q37371673 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Mycobacterium tuberculosis | Q130971 |
P304 | page(s) | 629-648 | |
P577 | publication date | 2014-11-10 | |
P1433 | published in | Journal of Enzyme Inhibition and Medicinal Chemistry | Q15708877 |
P1476 | title | Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors as potential antituberculotics: development in the past decade | |
P478 | volume | 30 |
Q49915173 | Antitubercular activity of 1,2,3-triazolyl fatty acid derivatives |
Q35892439 | Design, development, drug-likeness, and molecular docking studies of novel piperidin-4-imine derivatives as antitubercular agents |
Q38892242 | Enoyl acyl carrier protein reductase inhibitors: an updated patent review (2011 - 2015). |
Q38547127 | Recently disclosed chemical entities as potential candidates for management of tuberculosis |
Search more.